Who Optimizes SG&A Costs Better? Sanofi or Bristol-Myers Squibb Company

Sanofi vs. Bristol-Myers: Who Manages SG&A Costs Better?

__timestampBristol-Myers Squibb CompanySanofi
Wednesday, January 1, 201456990000008565000000
Thursday, January 1, 201550010000009496000000
Friday, January 1, 201650020000009592000000
Sunday, January 1, 2017484900000010164000000
Monday, January 1, 201845510000009934000000
Tuesday, January 1, 201948710000009883000000
Wednesday, January 1, 202076610000009390000000
Friday, January 1, 202176900000009555000000
Saturday, January 1, 2022781400000010539000000
Sunday, January 1, 2023777200000010765000000
Monday, January 1, 202484140000009183000000
Loading chart...

Unleashing insights

Optimizing SG&A Costs: A Tale of Two Giants

In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Sanofi and Bristol-Myers Squibb Company have showcased contrasting strategies in this domain. From 2014 to 2023, Sanofi consistently reported higher SG&A expenses, peaking at approximately $10.8 billion in 2023. In contrast, Bristol-Myers Squibb's expenses fluctuated, reaching a high of around $7.8 billion in 2022.

Despite Sanofi's higher absolute costs, their expenses grew by about 26% over the period, while Bristol-Myers Squibb saw a 36% increase. This suggests that Sanofi may have a more stable cost management strategy. As these companies continue to innovate and expand, their ability to optimize SG&A costs will remain a key factor in maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025